The role of FcRn includes the maintenance of serum IgG and albumin levels and the delivery of antigen in the form of immune complexes to degradative compartments within cells. The FcRn–IgG interaction is strictly pH-dependent, with a maximum at pH 6, and becomes undetectable as near neutral pH is approached, a feature that is essential for efficient transport. IgG transport between the blood and

Ponatinib concentration interstitial compartments may proceed by convection through paracellular pores in the vascular endothelium, or via FcRn-mediated transcytosis across vascular endosomal cells. Because of the redundancy of the transport systems, high-dose IVIG may help to block FcRn resulting in the enhanced clearance of pathogenic autoantibodies, but will never be able to block it completely, as

indicated in several experimental studies to date [42]. Although improving the binding of IgG to FcRn in vitro generally translates to an improved serum IgG half-life in vivo, this is not always the case. Recombinant therapeutics genetically engineered to contain IgG fragments with the CH2–CH3 domain that binds to FcRn can have significantly prolonged half-life due to protection of catabolism through FcRn binding. However, increased binding affinity to the FcRn does not appear to be proportional to the half-life extension. For example, when comparing variants of Herceptin antibody (an ERBB2-specific human IgG1 against mammary tumour cells) with a threefold LDE225 nmr increase in FcRn binding at acidic pH and another variant with a 12-fold increased binding at acidic pH and also enhanced binding at more neutral pH,

both antibodies exhibited similar half-lives when tested in a humanized FcRn transgenic mouse model [43]. Increased binding may enhance degradation of IgG under neutral Exoribonuclease conditions. Clearly, there is an obvious need to have a better understanding of FcRn in the exact regulation of IgG-mediated responses and half-life in vivo. Research in immunoglobulin therapy with IVIG or SCIG has shown that therapy targets and treatment options evolve in parallel. Achieving good clinical outcomes to enable a state of health as found in immunocompetent individuals is achievable with the use of 0·4–0·6 g/kg/month for many patients with PI, although some patients may require higher doses. For patients with autoimmune neuropathies, an empirically derived starting dose of 2 g/kg is used frequently in the acute setting as in Guillain–Barré syndrome. For maintenance treatment, evidence from a recent randomized placebo-controlled trial in chronic inflammatory demyelinating neuropathy suggests that a dose of 1 g/kg every 3 weeks is sufficient to maintain strength [44]. Indications for review of immunoglobulin doses in patients with PI and autoimmune neuropathies are summarized in Table 5.